CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling